March 18, 2014—The Obama administration proposes to audit and survey drugmakers more often to ensure they are fulfilling their Medicaid drug rebate obligations and to increase penalties for those that knowingly report false information for the calculation of rebates. … [Read more...]
340B Savings Critical for Ore. Health Centers, Study Concludes
Says mandated pass-through to MCOs could reduce access to medicines, servicesMarch 12, 2014—Requiring Oregon health centers to give the state all of their 340B savings on drugs for Medicaid beneficiaries, whose care is mainly managed and paid for by the state's new Medicaid coordinated care organizations, "may not actually be effective and could adversely impact patient care," a new study concludes. … [Read more...]
HRSA to Issue Three More 340B Regulations
Rules will create dispute resolution system and establish sanctions for manufacturers and providersMarch 6, 2014—While attention has focused on the forthcoming comprehensive regulation for the 340B program, aka the "mega-reg," the Health Resources and Services Administration is moving ahead with three other significant program regulations. … [Read more...]
HRSA Sketches out Its Priorities for 340B Funding
Verification of ceiling prices emerges as an area of focusMarch 5, 2014—Details about the Health Resources and Services Administration's (HRSA) policy priorities for the 340B program this fiscal year and next have emerged in a drug industry newsletter and in a supplement to President Obama's budget request to Congress. … [Read more...]
White House Seeks $17 Million for 340B Program
$7 million would come from user fee on purchasesMarch 4, 2014—The Obama administration is seeking $17 million for the 340B drug discount program in fiscal 2015, consisting of $10 million in appropriated funds and $7 million from a 0.1 percent user fee on 340B drug purchases. … [Read more...]
CMS OK’s California’s 340B Medicaid Carve-Out Ban and AAC Billing Requirement
Lawsuit over the policy is now before a federal appeals courtFebruary 28, 2014—The federal Centers for Medicare and Medicaid Services (CMS) has approved California Medicaid's 2009 policy requiring 340B covered entities to "carve in" their Medicaid purchases and to pass their 340B discounts on to Medicaid by billing such drugs at no more than actual acquisition cost (AAC) plus a dispensing fee. … [Read more...]
That Takes Chutzpah
We’ve noticed that Eli Lilly and Co. has been taking pot shots at the 340B program calling for more oversight and transparency. This from a company that agreed to plead guilty and pay $1.4 billion for promoting its antipsychotic drug Zyprexa for uses not approved by the Food and Drug Administration including marketing it to elderly patients with dementia. Health care providers … [Read more...]